Objective  To investigate the efficacy and safety of human immunoglobulin for intravenous injection (IVIG) in treating COVID-19 patients by Meta-analysis. Methods Between 1 January 2020 and 31 July 2021, randomized controlled trials (RCTs) and cohort studies referred to IVIG and COVID-19 were searched from Cochrane Library, PubMed, China National Knowledge Infrastructure (CNKI) and China Biology Medicine disc (CBM). Quality evaluation was performed according to Cochrane Handbook for Systematic Reviews and Meta-analysis was conducted with RevMan 5.3 Software. Results Eleven studies were retrieved, including 4 RCTs and 7 cohort studies. The result of the Meta-analysis showed that the mortality rate of critical ill COVID-19 patients could be relieved significantly by IVIG [risk ratio (RR)=0.67, 95% confidence interval (CI): 0.52-0.85, P=0.001, I²=7%].In severe patients, IVIG could also improve patients’ survival though significant statistical difference was not achieved [RR=0.78, 95% CI: 0.52-1.18, P=0.24, I²=49%]. The incidence of adverse reactions of IVIG in patients with COVID-19 was 0.0%-5.9%, and the majority was manifested in mild to moderate palpitation, dizziness, rash, and swelling at infusion site. Conclusion IVIG can improve the survival of critical ill COVID-19 patients effectively, with excellent safety. In severe patients, it is necessary to further explore the starting time and recommended dosage of IVIG, thus serving clinical practice better.